Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH

Abstract

The COVID-19 pandemic is an ongoing global healthcare crisis. Based on reports of atypically located thromboses following vaccination with the AstraZeneca COVID-19 vaccine, the Society of Thrombosis and Haemostasis Research (GTH) has issued guidance statements on the recognition, diagnosis, and treatment of this rare complication. It shares pathophysiological features with heparin-induced thrombocytopenia (HIT) and is referred to as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). Die COVID-19 Pandemie stellt eine andauernde globale Gesundheitskrise dar. Basierend auf den Berichten über atypisch lokalisierte Thrombosen nach Impfung mit dem AstraZeneca COVID-19 Vakzin hat die Gesellschaft für Thrombose- und Hämostaseforschung (GTH) Handlungsempfehlungen zur Erkennung, Diagnostik und Therapie dieser seltenen Komplikation formuliert. Ihre Pathophysiologie ähnelt derjenigen der Heparin-induzierten Thrombozytopenie (HIT) und wird als Vakzin-induzierte prothrombotische Immunthrombozytopenie (VIPIT) bezeichnet. Received: 29 March 2021 Accepted: 30 March 2021 Publication Date: 01 April 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany